Effect of Premedication With Pronase on Mucosal Cleanliness During EGD
NCT ID: NCT06713421
Last Updated: 2025-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
3000 participants
INTERVENTIONAL
2024-12-01
2025-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Application of OE in Diagnosis of EGC
NCT04720521
Gastrointestinal Endoscopy Artificial Intelligence Cloud Platform in Gastrointestinal Endoscopy Screening
NCT05435872
AQCS for Detection of Early Cancer and Precancerous Lesions on Upper Gastrointestinal Tract
NCT04720924
Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer
NCT02030769
Lifestyle Intervention for Prevention of Gastric Neoplasm
NCT02679495
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A1:Dimeticone+Pronase+Postural Exercise group
Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3. Then the patients are asked to take a 3-minute postural exercise.
Dimethicone+Pronase
Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3.
with Postural Exercise
After the premedication is administered orally approximately 15-20 minutes before EGD, patients are asked to take a 3-minute postural exercise.
A2:Dimeticone+Pronase group
Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3. Then the patients sit quietly awaiting examination.
Dimethicone+Pronase
Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3.
without Postural Exercise.
After the premedication is administered orally approximately 15-20 minutes before EGD, patients sit quietly awaiting examination.
B1:Dimeticone+Postural Exercise group
Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder. Then the patients are asked to take a 3-minute postural exercise.
Dimethicone
Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder.
with Postural Exercise
After the premedication is administered orally approximately 15-20 minutes before EGD, patients are asked to take a 3-minute postural exercise.
B2:Dimeticone group
Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder. Then the patients sit quietly awaiting examination.
Dimethicone
Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder.
without Postural Exercise.
After the premedication is administered orally approximately 15-20 minutes before EGD, patients sit quietly awaiting examination.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dimethicone+Pronase
Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3.
Dimethicone
Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder.
with Postural Exercise
After the premedication is administered orally approximately 15-20 minutes before EGD, patients are asked to take a 3-minute postural exercise.
without Postural Exercise.
After the premedication is administered orally approximately 15-20 minutes before EGD, patients sit quietly awaiting examination.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Voluntarily participate in the trial and sign the informed consent.
Exclusion Criteria
2. esophageal stricture, complete pyloric obstruction and gastroparesis caused by various reasons;
3. diagnosed malignant tumors of the upper digestive tract;
4. a history of upper gastrointestinal surgery;
5. severe heart, liver and kidney diseases, and the doctor judges that it is not suitable for painless gastroscopy;
6. serious mental illness;
7. pregnancy or breastfeeding;
8. an allergy to pronase or dimeticone;
9. current participation in other clinical trials and in the follow-up or drug washout period;
10. patients considered by the investigator to be unsuitable for this study
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fujian Provincial Hospital
OTHER
Huashan Hospital
OTHER
The Second Affiliated Hospital of Harbin Medical University
OTHER
First Affiliated Hospital of Harbin Medical University
OTHER
Red Cross Hospital, Hangzhou, China
OTHER
The Affiliated Hospital of Inner Mongolia Medical University
OTHER
Yuebei People's Hospital
OTHER
Longgang District People's Hospital of Shenzhen
OTHER
Huadu District People's Hospital of Guangzhou
OTHER
Liaocheng People's Hospital
OTHER
Qilu Hospital of Shandong University
OTHER
The Second Affiliated Hospital of Shandong First Medical University
OTHER
Anqing Municipal Hospital
OTHER
Jiujiang No.1 People's Hospital
OTHER
Kunshan Hospital of Traditional Chinese Medicine
UNKNOWN
Nanjing Gaochun People's Hospital
OTHER
Taizhou First People's Hospital
OTHER
Hengshui People's Hospital
OTHER
Affiliated Hospital of Hebei University
OTHER
Second Affiliated Hospital of Xi'an Jiaotong University
OTHER
Taihe Hospital
OTHER
ZhuZhou Central Hospital
OTHER
The Second Affiliated Hospital of Kunming Medical University
OTHER
First Affiliated Hospital of Kunming Medical University
OTHER
Subei People's Hospital of Jiangsu Province
OTHER
The Affiliated Hospital Of Southwest Medical University
OTHER
The Second Affiliated Hospital of Chongqing Medical University
OTHER
Loudi Central Hospital
OTHER
Beijing Tiantan Hospital
OTHER
Peking Union Medical College Hospital
OTHER
The First People's Hospital of Lin'an District, Hangzhou
UNKNOWN
Zhejiang Provincial People's Hospital
OTHER
Jining Medical University
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Zhoushan Hospital, Zhejiang
UNKNOWN
General Hospital of Ningxia Medical University
OTHER
Yunnan Cancer Hospital
OTHER
Xinghua City People's Hospital
UNKNOWN
Beijing Friendship Hospital, Captial Medical University
UNKNOWN
Beijing Chao-Yang Hospital, Captial Medical University
UNKNOWN
The People's Hospital of JiangMen
UNKNOWN
The First People's Hospital of TianMen in Hubei Province
UNKNOWN
THE FIRST AFFILIATED HOSPITAL OF SHIHEZI UNIVERSITY
UNKNOWN
Changhai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Luowei Wang, MD
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luowei Wang, MD
Role: PRINCIPAL_INVESTIGATOR
Changhai hosipital, Shanghai
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changhai hosipital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EPPMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.